Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP02 vs Irinotecan vs Docetaxel in Advanced Gastric Cancer
NCT00813072Phase 2Completed
- Sponsor
- PharmaEngine, Inc.
- Start
- Nov 2007
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of irinotecan liposome injection in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by PharmaEngine, Inc. Primary endpoint: Objective Tumor Response. Started Nov 2007; status: completed.
02
Drugs
irinotecan liposome injection
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00813072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00813072.